Navigation Links
Data Published in Circulation Journal Show OrbusNeich's Genous™ Stent Is Safe and Effective in Elderly Patients

HONG KONG, Oct. 25, 2011 /PRNewswire/ -- OrbusNeich today announced the publication of 12-month follow-up data from the e-HEALING (Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth) registry in Circulation Journal that show the Genous Stent is safe and effective in elderly patients.

In the study, no significant difference in stent thrombosis (ST) was observed at 12 months between elderly patients (aged 65 or older) and younger patients. The target lesion revascularization (TLR) rate was not significantly higher with increasing age. Target vessel failure (TVF), the main outcome of the study, was observed more often in elderly patients; TVF occurred in 11.7 percent of patients over the age of 75, in 8.8 percent of patients between the ages of 65 and 74, and in 7 percent of patients younger than 65. The increased rate of TVF in elderly patients was driven mainly by increased mortality.

"Early discontinuation of dual antiplatelet therapy (DAPT) has been identified as a major predictor for the occurrence of ST, and for this reason the elderly are at a particularly high-risk for ST due to their expected non-compliance with DAPT," said Dr. Andres Iniguez of the University of Vigo, Spain. "The elderly comprise an important subgroup of patients for whom long-term DAPT may not be advisable, and these data show that in patients over 65 the Genous Stent was safe and did not lead to an increased risk of ST despite their lower compliance."

The registry's main outcome was TVF at 12-month follow-up, defined as the composite of cardiac death or myocardial infarction (MI) unless unequivocally attributable to a non-target vessel and target vessel revascularization (TVR). Secondary outcomes were the composite of cardiac death, MI and clinically-indicated TLR, the individual outcomes all-cause death, cardiac death, MI (non-Q-wave or Q-wave), TLR, TVR, ST, major and minor bleeding and stroke.

e-HEALING, a multi-center, worldwide prospective clinical registry conducted at 144 centers in 31 countries outside of the United States, included 4,939 patients with at least one lesion suitable for non-urgent percutaneous coronary intervention (PCI) and Genous Stent implantation. In the patient population, 2,651 were under the age of 65, 1,403 were between the ages of 65 and 74, 794 were between the ages of 75 and 84, and 75 were over the age of 85. Elderly patients were defined as patients over the age of 65 and the very elderly as patients over the age of 75.

About Genous  

Genous is OrbusNeich's patented endothelial progenitor cell (EPC) capture technology that promotes the accelerated natural healing of the vessel wall after the implantation of blood-contact devices such as stents. The technology consists of an antibody surface coating that attracts EPCs circulating in the blood to the device to form an endothelial layer that provides protection against thrombosis and modulates restenosis.

The Genous Stent, which has been commercially available in more than 60 countries since 2005, has been proven as a safe, effective alternative to drug eluting stents and is supported by data from more than 6,000 patients in company-sponsored clinical studies. There is a growing body of evidence from multiple clinical studies that the Genous Stent is effective for patients who are non-responsive to or cannot tolerate long-term dual antiplatelet therapy.

About OrbusNeich

OrbusNeich is a global company that designs, develops, manufactures and markets innovative medical devices for the treatment of vascular diseases. Current products are the world's first pro-healing stent, the Genous Stent, as well as other stents and balloons marketed under the names of Azule™, R stent, Scoreflex™, Sapphire™, Sapphire II and Sapphire NC. Development stage products include the Combo™ Dual Therapy Stent, the only dual therapy stent to both accelerate endothelial coverage and control neo-intimal proliferation through the combination of the Genous pro-healing technology with an abluminal sirolimus drug elution. OrbusNeich is headquartered in Hong Kong and has operations in Shenzhen, China; Fort Lauderdale, Fla.; Hoevelaken, The Netherlands; and Tokyo, Japan. OrbusNeich supplies medical devices to interventional cardiologists in more than 60 countries. For more information, visit

Follow OrbusNeich on Twitter at, and learn more about the company and the Genous technology on OrbusNeich's YouTube Channel:

SOURCE OrbusNeich
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
2. Adlyfe Study on the Detection of Misfolded Proteins Published in the Journal Transfusion
3. Nebivolol Lowers Blood Pressure in Mild-to-Moderate Hypertensive Patients as Demonstrated in a Study Published in the Journal of Clinical Hypertension
4. Results from Study Evaluating PROCRIT(R) in Intensive Care Unit Patients Published in New England Journal of Medicine
5. Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
6. Study Published in Endocrinology Reports Potential of Modigene Technology to Extend Duration of Protein Drugs
7. New Data Published in Neurology Show Once-Daily Lamictal XR Significantly Reduced Partial Seizures in Patients with Epilepsy
8. Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine
9. Nebivolol Lowers Blood Pressure in African Americans With Stage I-II Hypertension as Demonstrated in a Study Published in the Journal of Clinical Hypertension
10. UPDATE: Nebivolol Lowers Blood Pressure in African Americans With Stage I-II Hypertension as Demonstrated in a Study Published in the Journal of Clinical Hypertension
11. Tumor Eradication Article Published by Cancer Research
Post Your Comments:
(Date:11/26/2015)... Carolina , 26 november 2015 /PRNewswire/ ... (AAIPharma/CML) kondigt de geplande investering aan van ... van de laboratoria en het mondiale hoofdkantoor ... De uitbreiding zal resulteren in extra kantoorruimte ... voldaan aan de groeiende behoeften van de ...
(Date:11/26/2015)... and Markets ( ) has announced the addition of ... - Rise in Cardiac Disorders and Growing Awareness among People ... Boston scientific and others. ... others. --> The market is dominated by ... scientific and others. Asia ...
(Date:11/26/2015)... DUBLIN , November 26, 2015 ... has announced the addition of the  ... in the Global Cell Surface Testing ... Opportunities" report to their offering.  ... the addition of the  "2016 Future ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... November 27, 2015 , ... ... 27th edition of USA Today in Atlanta, Dallas, New York, Minneapolis, South Florida, ... The digital component is distributed nationally, through a vast social media strategy and ...
(Date:11/27/2015)... DE (PRWEB) , ... November 27, 2015 , ... ... member of the well-respected Microsoft Dynamics SL User Group (MSDSLUG). Recognized as Microsoft’s ... an independent group of Microsoft Dynamics SL software users, partners, industry experts and ...
(Date:11/27/2015)... ... November 27, 2015 , ... CBD College is proud to ... Programs (CAAHEP) awarded accreditation to its Diagnostic Medical Sonography program. CBD College is honored ... one of twelve colleges and universities in the state of California make the cut. ...
(Date:11/27/2015)... ... November 27, 2015 , ... Indosoft Inc., developer ... incorporation of Asterisk 11 LTS (Long Term Support) into its Q-Suite 5.10 product ... Q-Suite 5.10 up-to-date with a version of Asterisk that will receive not only ...
(Date:11/26/2015)... ... November 26, 2015 , ... Somu Sivaramakrishnan announced today that ... Somu now offers travelers, value and care based Travel Services, including exclusive pricing ... well as, cabin upgrades and special amenities such as, shore excursions, discounted fares, ...
Breaking Medicine News(10 mins):